Investor Relations

OPKO Health Announces Leadership Changes at BioReference Laboratories more »

OPKO'S GeneDx Announces Research Collaboration with Radboud University Medical Center more »

OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy more »

OPKO Health Reports 2017 Third Quarter Highlights and Financial Results more »

Investor Relations

Investor Relations Contact:
LHA
Anne Marie Fields
212-838-3777
afields@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com

  • Stock Information


Ticker OPK Exchange NASDAQ
Last Price 3.80 Change 0.18 up
Open 3.66 Previous Close 3.62
Day High 3.83 Day Low 3.65
52-Week High 8.69 52-Week Low 3.55
Quotes delayed at least 20 minutes. Information provided by eSignal.

Email  Sign up for email alerts